Inotek closes enrolment in Phase II trial of trabodenoson + latanoprost for glaucoma

Inotek Pharmaceuticals has closed patient enrolment in the Phase II clinical trial of fixed-dose combination (FDC) of trabodenoson and latanoprost to treat patients with glaucoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news